JAZZ

Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds.

Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The Zacks Rank #1 stocks have averaged +23.86% annual returns since 1988, more than double the S&P 500.

Style Scores (Value, Growth, Momentum, and VGM) help narrow down top-rated stocks by evaluating their characteristics. Jazz Pharmaceuticals is highlighted as a stock to watch with a #3 Hold rank and VGM Score of A.

Axsome Therapeutics (AXSM) reported strong first-half 2026 results with its lead drug Auvelity generating $333 million in sales, up 54.2% year-over-year. The company is expanding Auvelity's market reach through FDA approval for Alzheimer's agitation treatment and a phase III smoking cessation study. Additional revenue support comes from Sunosi ($66.5M sales) and newly launched Symbravo ($6.3M sales), though the company faces intense competition in the CNS and migraine markets.